Updated:
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, led by CEO Jack Zhang, operates as a specialty pharma company focused on complex injectable and inhalation drugs.
Amphastar Pharmaceuticals
Founded in 1996 by Jack Zhang and colleagues, Amphastar Pharmaceuticals researches, develops, manufactures and markets generic and branded injectable drugs. Zhang, a former scientist, structured the company around the technical challenge of producing molecules that are difficult to formulate, keeping generic competition low. The firm listed on the Nasdaq in 2014 and today has a market capitalization exceeding $2 billion (per public record, May 2026). Amphastar's strategy concentrates on complex, hard-to-manufacture injectables, inhalation products, and intranasal drugs. Its portfolio spans nadroparin, naloxone, epinephrine, and a growing biosimilar pipeline anchored by its FDA-approved glucagon and teriparatide products. The company allocates significant capital to its internal biologics division, Amphastar Biologics, which operates a dedicated manufacturing campus in California. In May 2024, Amphastar acquired BAQSIMI, a ready-to-use glucagon rescue pen, from Eli Lilly for approximately $1.075 billion in cash and future milestones — its largest single deployment to date, immediately adding an established branded product to the commercial portfolio. Amphastar operates from a sprawling manufacturing and R&D complex in Rancho Cucamonga, California, with additional facilities in Massachusetts, France, and China. As of its most recent filings, the company employs roughly 1,700 professionals across these sites. The international subsidiary, Amphastar France Pharmaceuticals, manufactures nadroparin and enoxaparin for European markets. Amphastar also maintains a dedicated philanthropic subsidiary, the Amphastar International Foundation, run by Jason Shandell. The firm differs structurally from most specialty pharma companies by running an internally funded, self-contained development and manufacturing engine without relying on a partner-centric licensing model. Zhang's continued role as CEO, combined with a board that includes the company's founders, provides a multi-decade time horizon on capital allocation decisions — a posture typically associated with private family capital rather than a public company.
General information
Firm type
Asset Manager
Year founded
1996
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Rancho Cucamonga
Corporate office
Rancho Cucamonga, CA, United States
Principals
Jack Y. Zhang
President, CEO, and Director
William J. Peters
Chief Financial Officer and Executive Vice President
Jason Shandell
President of Amphastar's International Foundation
Sector focus
Frequently asked questions
Who runs investment and capital allocation decisions at Amphastar?
Capital allocation is directed by CEO Jack Zhang and CFO William Peters, who jointly oversee the pipeline prioritization and acquisition strategy. The board, which includes long-standing founding scientists, approves major transactions. The $1.075 billion BAQSIMI acquisition in 2024 was the most significant recent deployment (per the firm's SEC filings, 2024).
How does Amphastar source its pipeline of generic drug candidates?
Amphastar relies on an internal R&D team that identifies molecules with high technical barriers to entry. The firm specifically targets drugs that are difficult to manufacture, where formulation patents or complex production processes limit the number of generic competitors. Its biosimilar pipeline is developed through its Amphastar Biologics subsidiary. The company also conducts manufacturing and product development at its French and Chinese subsidiaries for certain product lines.
Is Amphastar structured purely as an operating company, or does it have an investment arm?
Amphastar operates as a fully integrated pharmaceutical company but directs significant capital towards internal pipeline investment, akin to a self-funding R&D vehicle. The 2024 BAQSIMI acquisition from Eli Lilly was a balance-sheet transaction, not a fund-managed deal. The firm does not maintain a separate investment management entity; capital allocation is managed by the corporate leadership team.
What role does the manufacturing network play in Amphastar's competitive position?
Manufacturing is Amphastar's primary structural advantage. The company owns and operates facilities in California, Massachusetts, France, and China, allowing it to control the full production chain for complex molecules. Amphastar Biologics' dedicated campus is a key asset for its biosimilar ambitions. Vertical integration in manufacturing allows the firm to defend margins on drugs where sterile injectable production remains a barrier.
What is the significance of Amphastar Biologics?
Amphastar Biologics is the firm's designated unit for developing biosimilar and biologic products. It operates a purpose-built manufacturing campus in California. The unit represents the company's push beyond traditional small-molecule generics into higher-value biologic products, with FDA-approved teriparatide and glucagon already in its commercial portfolio.
How does Amphastar handle philanthropic or mission-driven capital?
The firm maintains the Amphastar International Foundation, a legally separate philanthropic entity led by Jason Shandell. The foundation focuses on educational and health-related initiatives. The operating company is a for-profit Nasdaq-listed entity (AMPH) and does not blend philanthropic and commercial capital within its corporate treasury.
What is Amphastar's posture on external partnerships versus internal development?
Amphastar has historically favored organic development over licensing. The $1.075 billion acquisition of BAQSIMI from Eli Lilly in 2024 marked a notable expansion of its external deal activity. The company generally partners only for international distribution of its own manufactured products, not for in-licensing early-stage candidates.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: